Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.

ABSTRACT: The liver maintains a balance between immune tolerance and activation in its role as a filtration system. Chronic inflammation disrupts this immune microenvironment, thereby allowing for the rise and progression of cancer. Hepatocellular carcinoma (HCC) is a liver tumor generally diagnosed in the setting of chronic liver disease. When diagnosed early, the primary treatment is surgical resection, liver transplantation, or liver directed therapies. Unfortunately, patients with HCC often present at an advanced stage or with poor liver function, thereby limiting options. To further complicate matters, most systemic therapies are relatively limited and ineffective among patients with advanced disease. Recently, the IMbrave150 trial demonstrated that the combination of atezolizumab and bevacizum

SUBMITTER: Ruff SM 

PROVIDER: S-EPMC10297531 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature